22 / 38
How to choose the best front line therapy
for metastatic
EGFR
mutant NSCLC
•
Therapy most biologically sound
•
Targeted therapy with immediate efficacy—both
systemic and CNS
•
Therapy with low to modest toxicity profile
•
Therapy that will prolong survival
•
Impact on subsequent therapy—ultimately, use the
best drug first